A Cochrane review included 21 randomized studies involving 2,187 adults with chronic neuropathic pain. Five studies tested CBD-dominant medicines in about 200 people. Compared with placebo, these medicines did not clearly increase the chance of achieving at least 50% pain relief. The certainty of this evidence was very low.

Other findings are more encouraging but less decisive. Adults receiving several oral cannabinoid combinations in a real-world study reported improvement. However, there was no placebo group, only 168 of 276 recruits completed all questionnaires, and the main analysis focused on completers. The products also

For sleep, a meta-analysis combined six randomized trials involving 1,077 adults with insomnia, poor sleep, or neither condition. Cannabinoids as a broad category improved self-reported sleep quality, but results varied greatly. CBD-only therapies did not significantly improve sleep quality compared with placebo. Benefits from THC-containing or other cannabinoid products cannot be assigned to CBD.

The anxiety evidence in these adult studies is limited. In a double-blind dental trial, a CBD-rich cannabis extract did not reduce dental anxiety more than placebo. It also did not improve postoperative pain. Dental anxiety is a specific short-term situation, so this

Safety depends on the formulation and the other substances a person takes. In a controlled laboratory study of 31 healthy adults, researchers combined hydromorphone, an opioid, with 50, 100, or 200 milligrams of CBD. The highest amount produced more self-reported bad effects and adverse effects than the lower amounts.

CBD altered some measured effects of hydromorphone, showing that combinations can behave differently from either substance alone. That short experiment did not establish how CBD alone affects driving, work, or everyday alertness. The adult studies reviewed here do not reliably estimate liver-enzyme risk

Clinical studies test particular preparations. Retail products may be sold as CBD isolate, hemp extract, full-spectrum CBD, or blends containing CBD acid and other cannabinoids. A survey of people with fibromyalgia found different medication-substitution patterns among users of isolate, hemp, and CBD-cannabis products. Those reports describe experiences, not proof of cause.

The real-world capsule study also tested several cannabinoid mixtures rather than one standardized CBD product. The human evidence reviewed here does not verify the labeled strength, THC content, contaminants, or batch consistency of the wider retail market. It also does not quantify

A Cochrane review included 21 randomized studies involving 2,187 adults with chronic neuropathic pain. Five studies tested CBD-dominant medicines in about 200 people. Compared with placebo, these medicines did not clearly increase the chance of achieving at least 50% pain relief. The certainty of this evidence was very low.

Other findings are more encouraging but less decisive. Adults receiving several oral cannabinoid combinations in a real-world study reported improvement. However, there was no placebo group, only 168 of 276 recruits completed all questionnaires, and the main analysis focused on completers. The products also

For sleep, a meta-analysis combined six randomized trials involving 1,077 adults with insomnia, poor sleep, or neither condition. Cannabinoids as a broad category improved self-reported sleep quality, but results varied greatly. CBD-only therapies did not significantly improve sleep quality compared with placebo. Benefits from THC-containing or other cannabinoid products cannot be assigned to CBD.

The anxiety evidence in these adult studies is limited. In a double-blind dental trial, a CBD-rich cannabis extract did not reduce dental anxiety more than placebo. It also did not improve postoperative pain. Dental anxiety is a specific short-term situation, so this

Safety depends on the formulation and the other substances a person takes. In a controlled laboratory study of 31 healthy adults, researchers combined hydromorphone, an opioid, with 50, 100, or 200 milligrams of CBD. The highest amount produced more self-reported bad effects and adverse effects than the lower amounts.

CBD altered some measured effects of hydromorphone, showing that combinations can behave differently from either substance alone. That short experiment did not establish how CBD alone affects driving, work, or everyday alertness. The adult studies reviewed here do not reliably estimate liver-enzyme risk

Clinical studies test particular preparations. Retail products may be sold as CBD isolate, hemp extract, full-spectrum CBD, or blends containing CBD acid and other cannabinoids. A survey of people with fibromyalgia found different medication-substitution patterns among users of isolate, hemp, and CBD-cannabis products. Those reports describe experiences, not proof of cause.

The real-world capsule study also tested several cannabinoid mixtures rather than one standardized CBD product. The human evidence reviewed here does not verify the labeled strength, THC content, contaminants, or batch consistency of the wider retail market. It also does not quantify